Trial watch: IDO inhibitors in cancer therapy

OncoImmunology

Volumn 3, Issue 10, 2014, Pages e957994-1-e957994-10

  Vacchelli, Erika ^a,b,c   Aranda, Fernando ^a,b   Eggermont, Alexander ^a   Sautès Fridman, Catherine ^b,d   Tartour, Eric ^e,f,g   Kennedy, Eugene P ^h   Platten, Michael ⁱ   Zitvogel, Laurence ^a,j   Kroemer, Guido ^a,b,e,g   Galluzzi, Lorenzo ^a,b,e  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^g HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^h NEWLINK GENETICS   (United States)

ⁱ GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^j University Paris XI   (France)

more..

Author keywords

1 methyl D tryptophan; INCB024360; indoximod; interferon ; NLG919; peptide based anticancer vaccines

Indexed keywords

4 AMINO N (3 CHLORO 4 FLUOROPHENYL) N' HYDROXY 1,2,5 OXADIAZOLE 3 CARBOXIMIDAMIDE; ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; DOCETAXEL; GEMCITABINE; HLA ANTIGEN; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE 1; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; INDOXIMOD; IPILIMUMAB; NLG 919; PACLITAXEL; PROGRAMMED DEATH 1 RECEPTOR; SIPULEUCEL T; TEMOZOLOMIDE; TOLL LIKE RECEPTOR 7; UNCLASSIFIED DRUG; VEMURAFENIB;

ANTIGEN PRESENTING CELL; ARTICLE; ASTROCYTOMA; CANCER GROWTH; CANCER STAGING; CANCER THERAPY; CARCINOMA; DRUG EFFICACY; DRUG SAFETY; GLIOMA; HUMAN; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; MELANOMA; METASTATIC MELANOMA; MYELODYSPLASTIC SYNDROME; NEOPLASM; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE CARCINOMA; PROTEIN EXPRESSION;

EID: 84921398751     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/21624011.2014.957994     Document Type: Article

References (177)

1. S.Lob, A.Konigsrainer, H.G.Rammensee, G.Opelz, P.Terness. Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat Rev Cancer 2009; 9:445-52; PMID:19461669; http://dx.doi.org/10.1038/nrc2639
2. J.R.Moffett, M.A.Namboodiri. Tryptophan and the immune response. Immunol Cell Biol 2003; 81:247-65; PMID:12848846; http://dx.doi.org/10.1046/j.1440-1711.2003.t01-1-01177.x
3. A.H.Mehler, W.E.Knox. The conversion of tryptophan to kynurenine in liver. II. The enzymatic hydrolysis of formylkynurenine. J Biol Chem 1950; 187:431-38; PMID:14794728
4. W.E.Knox, A.H.Mehler. The conversion of tryptophan to kynurenine in liver. I. The coupled tryptophan peroxidase-oxidase system forming formylkynurenine. J Biol Chem 1950; 187:419-30; PMID:14794727
5. S.Lob, A.Konigsrainer, D.Zieker, B.L.Brucher, H.G.Rammensee, G.Opelz, P.Terness. IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol Immunother 2009; 58:153-57; PMID:18418598; http://dx.doi.org/10.1007/s00262-008-0513-6
6. R.Metz, J.B.Duhadaway, U.Kamasani, L.Laury-Kleintop, A.J.Muller, G.C.Prendergast. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res 2007; 67:7082-87; PMID:17671174; http://dx.doi.org/10.1158/0008-5472.CAN-07-1872
7. S.J.Thackray, C.G.Mowat, S.K.Chapman. Exploring the mechanism of tryptophan 2,3-dioxygenase. Biochem Soc Trans 2008; 36:1120-23; PMID:19021508; http://dx.doi.org/10.1042/BST0361120
8. O.Hayaishi, R.Yoshida. Specific induction of pulmonary indoleamine 2,3-dioxygenase by bacterial lipopolysaccharide. Ciba Found Symp 1978:199-203; PMID:258162
9. R.Yoshida, O.Hayaishi. Induction of pulmonary indoleamine 2,3-dioxygenase by intraperitoneal injection of bacterial lipopolysaccharide. Proc Natl Acad Sci U S A 1978; 75:3998-4000; PMID:279015; http://dx.doi.org/10.1073/pnas.75.8.3998
10. Y.Urade, R.Yoshida, H.Kitamura, O.Hayaishi. Induction of indoleamine 2,3-dioxygenase in alveolar interstitial cells of mouse lung by bacterial lipopolysaccharide. J Biol Chem 1983; 258:6621-27; PMID:6343379
11. E.R.Pfefferkorn. Interferon gamma blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan. Proc Natl Acad Sci U S A 1984; 81:908-12; PMID:6422465; http://dx.doi.org/10.1073/pnas.81.3.908
12. D.H.Munn, E.Shafizadeh, J.T.Attwood, I.Bondarev, A.Pashine, A.L.Mellor. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 1999; 189:1363-72; PMID:10224276; http://dx.doi.org/10.1084/jem.189.9.1363
13. C.Guillonneau, M.Hill, F.X.Hubert, E.Chiffoleau, C.Herve, X.L.Li, M.Heslan, C.Usal, L.Tesson, S.Ménoret CD40Ig treatment results in allograft acceptance mediated by CD8CD45RC T cells, IFN-gamma, and indoleamine 2,3-dioxygenase. J Clin Invest 2007; 117:1096-106; PMID:17404623; http://dx.doi.org/10.1172/JCI28801
14. P.Hwu, M.X.Du, R.Lapointe, M.Do, M.W.Taylor, H.A.Young. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol 2000; 164:3596-99; PMID:10725715; http://dx.doi.org/10.4049/jimmu-nol.164.7.3596
15. P.Giannoni, G.Pietra, G.Travaini, R.Quarto, G.Shyti, R.Benelli, L.Ottaggio, M.C.Mingari, S.Zupo, G.Cutrona Chronic lymphocytic leukemia nurse-like cells express hepatocyte growth factor receptor (c-MET) and indoleamine 2,3-dioxygenase and display features of immunosuppressive type 2 skewed macrophages. Haematologica 2014; 99:1078-87; PMID:24561793; http://dx.doi.org/10.3324/haematol.2013.091405
16. R.Rani, M.B.Jordan, S.Divanovic, D.R.Herbert. IFN-gamma-driven IDO production from macrophages protects IL-4Ralpha-deficient mice against lethality during Schistosoma mansoni infection. Am J Pathol 2012; 180:2001-08; PMID:22426339; http://dx.doi.org/10.1016/j.ajpath.2012.01.013
17. R.Potula, L.Poluektova, B.Knipe, J.Chrastil, D.Heilman, H.Dou, O.Takikawa, D.H.Munn, H.E.Gendelman, Y.Persidsky. Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis. Blood 2005; 106:2382-90; PMID:15961516; http://dx.doi.org/10.1182/blood-2005-04-1403
18. J.Yu, Y.Wang, F.Yan, P.Zhang, H.Li, H.Zhao, C.Yan, F.Yan, X.Ren. Noncanonical NF-kappaB activation mediates STAT3-stimulated IDO upregulation in myeloid-derived suppressor cells in breast cancer. J Immunol 2014; 193:2574-86; PMID:25063873; http://dx.doi.org/10.4049/jimmunol.1400833
19. D.H.Munn, M.Zhou, J.T.Attwood, I.Bondarev, S.J.Conway, B.Marshall, C.Brown, A.L.Mellor. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998; 281:1191-93; PMID:9712583; http://dx.doi.org/10.1126/science.281.5380.1191
20. D.H.Munn, A.L.Mellor. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol 2013; 34:137-43; PMID:23103127; http://dx.doi.org/10.1016/j.it.2012.10.001
21. L.Pilotte, P.Larrieu, V.Stroobant, D.Colau, E.Dolusic, R.Frederick, E.De Plaen, C.Uyttenhove, J.Wouters, B.Masereel Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc Natl Acad Sci U S A 2012; 109:2497-502; PMID:22308364; http://dx.doi.org/10.1073/pnas.1113873109
22. H.J.Ball, A.Sanchez-Perez, S.Weiser, C.J.Austin, F.Astelbauer, J.Miu, J.A.McQuillan, R.Stocker, L.S.Jermiin, N.H.Hunt. Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene 2007; 396:203-13; PMID:17499941; http://dx.doi.org/10.1016/j.gene.2007.04.010
23. C.Uyttenhove, L.Pilotte, I.Theate, V.Stroobant, D.Colau, N.Parmentier, T.Boon, B.J.Van den Eynde. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003; 9:1269-74; PMID:14502282; http://dx.doi.org/10.1038/nm934
24. F.Fallarino, U.Grohmann, C.Vacca, C.Orabona, A.Spreca, M.C.Fioretti, P.Puccetti. T cell apoptosis by kynurenines. Adv Exp Med Biol 2003; 527:183-90; PMID:15206731; http://dx.doi.org/10.1007/978-1-4615-0135-0_21
25. T.Hayashi, J.H.Mo, X.Gong, C.Rossetto, A.Jang, L.Beck, G.I.Elliott, I.Kufareva, R.Abagyan, D.H.Broide 3-Hydroxyanthranilic acid inhibits PDK1 activation and suppresses experimental asthma by inducing T cell apoptosis. Proc Natl Acad Sci U S A 2007; 104:18619-24; PMID:18003900; http://dx.doi.org/10.1073/pnas.0709261104
26. D.H.Munn, M.D.Sharma, B.Baban, H.P.Harding, Y.Zhang, D.Ron, A.L.Mellor. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 2005; 22:633-42; PMID:15894280; http://dx.doi.org/10.1016/j.immuni.2005.03.013
27. L.Galluzzi, J.M.Bravo-San Pedro, G.Kroemer. Organelle-specific initiation of cell death. Nat Cell Biol 2014; 16:728-36; PMID:25082195; http://dx.doi.org/10.1038/ncb3005
28. + T cells is responsible for indoleamine 2,3-dioxygenase-dependent immune suppression. J Immunol 2009; 183:1022-31; PMID:19564344; http://dx.doi.org/10.4049/jimmunol.0900408
29. C.A.Opitz, U.M.Litzenburger, F.Sahm, M.Ott, I.Tritschler, S.Trump, T.Schumacher, L.Jestaedt, D.Schrenk, M.Weller An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 2011; 478:197-203; PMID:21976023; http://dx.doi.org/10.1038/nature10491
30. G.Frumento, R.Rotondo, M.Tonetti, G.Damonte, U.Benatti, G.B.Ferrara. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med 2002; 196:459-68; PMID:12186838; http://dx.doi.org/10.1084/jem.20020121
31. M.Della Chiesa, S.Carlomagno, G.Frumento, M.Balsamo, C.Cantoni, R.Conte, L.Moretta, A.Moretta, M.Vitale. The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function. Blood 2006; 108:4118-25; PMID:16902152; http://dx.doi.org/10.1182/blood-2006-03-006700
32. N.Sato, Y.Saga, H.Mizukami, D.Wang, S.Takahashi, H.Nonaka, H.Fujiwara, Y.Takei, S.Machida, O.Takikawa Downregulation of indoleamine-2,3-dioxygenase in cervical cancer cells suppresses tumor growth by promoting natural killer cell accumulation. Oncol Rep 2012; 28:1574-78; PMID:22923135; http://dx.doi.org/10.3892/or.2012.1984
33. A.Molano, P.A.Illarionov, G.S.Besra, C.Putterman, S.A.Porcelli. Modulation of invariant natural killer T cell cytokine responses by indoleamine 2,3-dioxygenase. Immunol Lett 2008; 117:81-90; PMID:18272236; http://dx.doi.org/10.1016/j.imlet.2007.12.013
34. V.P.Balachandran, M.J.Cavnar, S.Zeng, Z.M.Bamboat, L.M.Ocuin, H.Obaid, E.C.Sorenson, R.Popow, C.Ariyan, F.Rossi Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med 2011; 17:1094-100; PMID:21873989; http://dx.doi.org/10.1038/nm.2438
35. J.D.Mezrich, J.H.Fechner, X.Zhang, B.P.Johnson, W.J.Burlingham, C.A.Bradfield. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol 2010; 185:3190-98; PMID:20720200; http://dx.doi.org/10.4049/jimmunol.0903670
36. L.Romani, F.Fallarino, A.De Luca, C.Montagnoli, C.D'Angelo, T.Zelante, C.Vacca, F.Bistoni, M.C.Fioretti, U.Grohmann Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. Nature 2008; 451:211-15; PMID:18185592; http://dx.doi.org/10.1038/nature06471
37. D.Favre, J.Mold, P.W.Hunt, B.Kanwar, P.Loke, L.Seu, J.D.Barbour, M.M.Lowe, A.Jayawardene, F.Aweeka Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci Transl Med 2010; 2:32ra6; PMID:20484731; http://dx.doi.org/10.1126/scitranslmed.3000632
38. R.Gandhi, D.Kumar, E.J.Burns, M.Nadeau, B.Dake, A.Laroni, D.Kozoriz, H.L.Weiner, F.J.Quintana. Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells. Nat Immunol 2010; 11:846-53; PMID:20676092; http://dx.doi.org/10.1038/ni.1915
39. M.A.Jenabian, M.Patel, I.Kema, C.Kanagaratham, D.Radzioch, P.Thebault, R.Lapointe, C.Tremblay, N.Gilmore, P.Ancuta Distinct tryptophan catabolism and Th17/Treg balance in HIV progressors and elite controllers. PLoS One 2013; 8:e78146; PMID:24147117; http://dx.doi.org/10.1371/journal.pone.0078146
40. B.Baban, P.R.Chandler, M.D.Sharma, J.Pihkala, P.A.Koni, D.H.Munn, A.L.Mellor. IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J Immunol 2009; 183:2475-83; PMID:19635913; http://dx.doi.org/10.4049/jimmunol.0900986
41. M.Platten, P.P.Ho, S.Youssef, P.Fontoura, H.Garren, E.M.Hur, R.Gupta, L.Y.Lee, B.A.Kidd, W.H.Robinson Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science 2005; 310:850-55; PMID:16272121; http://dx.doi.org/10.1126/science.1117634
42. N.T.Nguyen, A.Kimura, T.Nakahama, I.Chinen, K.Masuda, K.Nohara, Y.Fujii-Kuriyama, T.Kishimoto. Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc Natl Acad Sci U S A 2010; 107:19961-66; PMID:21041655; http://dx.doi.org/10.1073/pnas.1014465107
43. M.J.Park, K.S.Park, H.S.Park, M.L.Cho, S.Y.Hwang, S.Y.Min, S.Y.Min, M.K.Park, S.H.Park, H.Y.Kim. A distinct tolerogenic subset of splenic IDO(+)CD11b(+) dendritic cells from orally tolerized mice is responsible for induction of systemic immune tolerance and suppression of collagen-induced arthritis. Cell Immunol 2012; 278:45-54; PMID:23121975; http://dx.doi.org/10.1016/j.cellimm.2012.06.009
44. C.Orabona, P.Puccetti, C.Vacca, S.Bicciato, A.Luchini, F.Fallarino, R.Bianchi, E.Velardi, K.Perruccio, A.Velardi Toward the identification of a tolerogenic signature in IDO-competent dendritic cells. Blood 2006; 107:2846-54; PMID:16339401; http://dx.doi.org/10.1182/blood-2005-10-4077
45. F.Fallarino, U.Grohmann, S.You, B.C.McGrath, D.R.Cavener, C.Vacca, C.Orabona, R.Bianchi, M.L.Belladonna, C.Volpi The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol 2006; 176:6752-61; PMID:16709834; http://dx.doi.org/10.4049/jimmunol.176.11.6752
46. W.Chen, X.Liang, A.J.Peterson, D.H.Munn, B.R.Blazar. The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J Immunol 2008; 181:5396-404; PMID:18832696; http://dx.doi.org/10.4049/jimmunol.181.8.5396
47. A.L.Mellor, B.Baban, P.Chandler, B.Marshall, K.Jhaver, A.Hansen, P.A.Koni, M.Iwashima, D.H.Munn. Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J Immunol 2003; 171:1652-55; PMID:12902462; http://dx.doi.org/10.4049/jimmunol.171.4.1652
48. B.Baban, A.M.Hansen, P.R.Chandler, A.Manlapat, A.Bingaman, D.J.Kahler, D.H.Munn, A.L.Mellor. A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation. Int Immunol 2005; 17:909-19; PMID:15967784; http://dx.doi.org/10.1093/intimm/dxh271
49. S.B.Adikari, H.Lian, H.Link, Y.M.Huang, B.G.Xiao. Interferon-gamma-modified dendritic cells suppress B cell function and ameliorate the development of experimental autoimmune myasthenia gravis. Clin Exp Immunol 2004; 138:230-36; PMID:15498031; http://dx.doi.org/10.1111/j.1365-2249.2004.02585.x
50. D.H.Munn, M.D.Sharma, J.R.Lee, K.G.Jhaver, T.S.Johnson, D.B.Keskin, B.Marshall, P.Chandler, S.J.Antonia, R.Burgess Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 2002; 297:1867-70; PMID:12228717; http://dx.doi.org/10.1126/science.1073514
51. F.Fallarino, C.Orabona, C.Vacca, R.Bianchi, S.Gizzi, C.Asselin-Paturel, M.C.Fioretti, G.Trinchieri, U.Grohmann, P.Puccetti. Ligand and cytokine dependence of the immunosuppressive pathway of tryptophan catabolism in plasmacytoid dendritic cells. Int Immunol 2005; 17:1429-38; PMID:16172135; http://dx.doi.org/10.1093/intimm/dxh321
52. F.Fallarino, C.Asselin-Paturel, C.Vacca, R.Bianchi, S.Gizzi, M.C.Fioretti, G.Trinchieri, U.Grohmann, P.Puccetti. Murine plasmacytoid dendritic cells initiate the immunosuppressive pathway of tryptophan catabolism in response to CD200 receptor engagement. J Immunol 2004; 173:3748-54; PMID:15356121; http://dx.doi.org/10.4049/jimmu-nol.173.6.3748
53. M.D.Sharma, B.Baban, P.Chandler, D.Y.Hou, N.Singh, H.Yagita, M.Azuma, B.R.Blazar, A.L.Mellor, D.H.Munn. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest 2007; 117:2570-82; PMID:17710230; http://dx.doi.org/10.1172/JCI31911
54. R.A.Derks, E.Jankowska-Gan, Q.Xu, W.J.Burlingham. Dendritic cell type determines the mechanism of bystander suppression by adaptive T regulatory cells specific for the minor antigen HA-1. J Immunol 2007; 179:3443-51; PMID:17785778; http://dx.doi.org/10.4049/jimmunol.179.6.3443
55. D.H.Munn, M.D.Sharma, D.Hou, B.Baban, J.R.Lee, S.J.Antonia, J.L.Messina, P.Chandler, P.A.Koni, A.L.Mellor. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 2004; 114:280-90; PMID:15254595; http://dx.doi.org/10.1172/JCI200421583
56. C.Conrad, M.Gilliet. Plasmacytoid dendritic cells and regulatory T cells in the tumor microenvironment: a dangerous liaison. Oncoimmunology 2013; 2:e23887; PMID:23762788; http://dx.doi.org/10.4161/onci.23887
57. V.Sisirak, J.Faget, N.Vey, J.Y.Blay, C.Menetrier-Caux, C.Caux, N.Bendriss-Vermare. Plasmacytoid dendritic cells deficient in IFNalpha production promote the amplification of FOXP3 regulatory T cells and are associated with poor prognosis in breast cancer patients. Oncoimmunology 2013; 2:e22338; PMID:23482834; http://dx.doi.org/10.4161/onci.22338
58. L.Senovilla, E.Vacchelli, J.Galon, S.Adjemian, A.Eggermont, W.H.Fridman, C.Sautès-Fridman, Y.Ma, E.Tartour, L.Zitvogel Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology 2012; 1:1323-43; PMID:23243596; http://dx.doi.org/10.4161/onci.22009
59. + T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells. Blood 2007; 109:3351-59; PMID:17158233; http://dx.doi.org/10.1182/blood-2006-07-034785
60. R.Planes, E.Bahraoui. HIV-1 Tat protein induces the production of IDO in human monocyte derived-dendritic cells through a direct mechanism: effect on T cells proliferation. PLoS One 2013; 8:e74551; PMID:24073214; http://dx.doi.org/10.1371/journal.pone.0074551
61. O.Manches, M.V.Fernandez, J.Plumas, L.Chaperot, N.Bhardwaj. Activation of the noncanonical NF-kappaB pathway by HIV controls a dendritic cell immunoregulatory phenotype. Proc Natl Acad Sci U S A 2012; 109:14122-27; PMID:22879398; http://dx.doi.org/10.1073/pnas.1204032109
62. R.S.Grant, H.Naif, S.J.Thuruthyil, N.Nasr, T.Littlejohn, O.Takikawa, V.Kapoor. Induction of indolamine 2,3-dioxygenase in primary human macrophages by human immunodeficiency virus type 1 is strain dependent. J Virol 2000; 74:4110-15; PMID:10756023; http://dx.doi.org/10.1128/JVI.74.9.4110-4115.2000
63. M.Huengsberg, J.B.Winer, M.Gompels, R.Round, J.Ross, M.Shahmanesh. Serum kynurenine-to-tryptophan ratio increases with progressive disease in HIV-infected patients. Clin Chem 1998; 44:858-62; PMID:9554499
64. I.Vujkovic-Cvijin, R.M.Dunham, S.Iwai, M.C.Maher, R.G.Albright, M.J.Broadhurst, R.D.Hernandez, M.M.Lederman, Y.Huang, M.Somsouk, Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism. Sci Transl Med 2013; 5:193ra91; PMID:23843452; http://dx.doi.org/10.1126/scitranslmed.3006438
65. + T regulatory cells. Blood 2007; 109:2871-77; PMID:17164341; http://dx.doi.org/10.1182/blood-2006-07-036863
66. A.Curti, M.Aluigi, S.Pandolfi, E.Ferri, A.Isidori, V.Salvestrini, I.Durelli, A.L.Horenstein, F.Fiore, M.Massaia Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. Leukemia 2007; 21:353-55; PMID:17170728; http://dx.doi.org/10.1038/sj.leu.2404485
67. A.J.Muller, J.B.DuHadaway, P.S.Donover, E.Sutanto-Ward, G.C.Prendergast. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 2005; 11:312-19; PMID:15711557; http://dx.doi.org/10.1038/nm1196
68. T.Tajiri, X.Liu, P.M.Thompson, S.Tanaka, S.Suita, H.Zhao, J.M.Maris, G.C.Prendergast, M.D.Hogarty. Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features. Clin Cancer Res 2003; 9:3345-55; PMID:12960121
69. K.Ge, J.DuHadaway, W.Du, M.Herlyn, U.Rodeck, G.C.Prendergast. Mechanism for elimination of a tumor suppressor: aberrant splicing of a brain-specific exon causes loss of function of Bin1 in melanoma. Proc Natl Acad Sci U S A 1999; 96:9689-94; PMID:10449755; http://dx.doi.org/10.1073/pnas.96.17.9689
70. M.Y.Chang, J.Boulden, J.B.Katz, L.Wang, T.J.Meyer, A.P.Soler, A.J.Muller, G.C.Prendergast. Bin1 ablation increases susceptibility to cancer during aging, particularly lung cancer. Cancer Res 2007; 67:7605-12; PMID:17699764; http://dx.doi.org/10.1158/0008-5472.CAN-07-1100
71. K.Ge, F.Minhas, J.Duhadaway, N.C.Mao, D.Wilson, R.Buccafusca, D.Sakamuro, P.Nelson, S.B.Malkowicz, J.Tomaszewski Loss of heterozygosity and tumor suppressor activity of Bin1 in prostate carcinoma. Int J Cancer 2000; 86:155-61; PMID:10738240; http://dx.doi.org/10.1002/(SICI)1097-0215(20000415)86:2<155::AID-IJC2>3.0.CO;2-M
72. M.Y.Chang, J.Boulden, E.Sutanto-Ward, J.B.Duhadaway, A.P.Soler, A.J.Muller, G.C.Prendergast. Bin1 ablation in mammary gland delays tissue remodeling and drives cancer progression. Cancer Res 2007; 67:100-07; PMID:17210688; http://dx.doi.org/10.1158/0008-5472.CAN-06-2742
73. K.Ge, J.Duhadaway, D.Sakamuro, R.Wechsler-Reya, C.Reynolds, G.C.Prendergast. Losses of the tumor suppressor BIN1 in breast carcinoma are frequent and reflect deficits in programmed cell death capacity. Int J Cancer 2000; 85:376-83; PMID:10652430; http://dx.doi.org/10.1002/(SICI)1097-0215(20000201)85:3<376::AID-IJC14>3.0.CO;2-1
74. T.Z.Iversen, L.Engell-Noerregaard, E.Ellebaek, R.Andersen, S.K.Larsen, J.Bjoern, C.Zeyher, C.Gouttefangeas, B.M.Thomsen, B.Holm Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase. Clin Cancer Res 2014; 20:221-32; PMID:24218513; http://dx.doi.org/10.1158/1078-0432.CCR-13-1560
75. R.C.Newton, P.A.Scherle, K.Bowman, X.Liu, Beatty, P.J.G.T.B.J.S.R.L.L.O'DwyerPJ, Gajewski T, Bowman J, Schaub R, Leopold L. Pharmacodynamic assessment of INCB024360, an inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), in advanced cancer patients. J Clin Oncol 2012; 30:abstr 2500
76. L.Ferdinande, C.Decaestecker, L.Verset, A.Mathieu, X.Moles Lopez, A.M.Negulescu, T.Van Maerken, I.Salmon, C.A.Cuvelier, P.Demetter. Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer. Br J Cancer 2012; 106:141-47; PMID:22108515; http://dx.doi.org/10.1038/bjc.2011.513
77. G.Brandacher, A.Perathoner, R.Ladurner, S.Schneeberger, P.Obrist, C.Winkler, E.R.Werner, G.Werner-Felmayer, H.G.Weiss, G.Göbel Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res 2006; 12:1144-51; PMID:16489067; http://dx.doi.org/10.1158/1078-0432.CCR-05-1966
78. K.Pan, H.Wang, M.S.Chen, H.K.Zhang, D.S.Weng, J.Zhou, W.Huang, J.J.Li, H.F.Song, J.C.Xia. Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma. J Cancer Res Clin Oncol 2008; 134:1247-53; PMID:18438685; http://dx.doi.org/10.1007/s00432-008-0395-1
79. R.Riesenberg, C.Weiler, O.Spring, M.Eder, A.Buchner, T.Popp, M.Castro, R.Kammerer, O.Takikawa, R.A.Hatz Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma. Clin Cancer Res 2007; 13:6993-7002; PMID:18056175; http://dx.doi.org/10.1158/1078-0432.CCR-07-0942
80. B.C.Creelan, S.Antonia, G.Bepler, T.J.Garrett, G.R.Simon, H.H.Soliman. Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer. Oncoimmunology 2013; 2:e23428; PMID:23802083; http://dx.doi.org/10.4161/onci.23428
81. C.Berthon, M.Fontenay, S.Corm, I.Briche, D.Allorge, B.Hennart, M.Lhermitte, B.Quesnel. Metabolites of tryptophan catabolism are elevated in sera of patients with myelodysplastic syndromes and inhibit hematopoietic progenitor amplification. Leuk Res 2013; 37:573-79; PMID:23453284; http://dx.doi.org/10.1016/j.leukres.2013.02.001
82. T.Yoshikawa, T.Hara, H.Tsurumi, N.Goto, M.Hoshi, J.Kitagawa, N.Kanemura, S.Kasahara, H.Ito, M.Takemura Serum concentration of L-kynurenine predicts the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP. Eur J Haematol 2010; 84:304-09; PMID:19995374; http://dx.doi.org/10.1111/j.1600-0609.2009.01393.x
83. T.Ishio, S.Goto, K.Tahara, S.Tone, K.Kawano, S.Kitano. Immunoactivative role of indoleamine 2,3-dioxygenase in human hepatocellular carcinoma. J Gastroenterol Hepatol 2004; 19:319-26; PMID:14748880; http://dx.doi.org/10.1111/j.1440-1746.2003.03259.x
84. + dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling. J Immunol 2005; 175:5601-05; PMID:16237046; http://dx.doi.org/10.4049/jimmunol.175.9.5601
85. G.Wingender, N.Garbi, B.Schumak, F.Jungerkes, E.Endl, D.von Bubnoff, J.Steitz, J.Striegler, G.Moldenhauer, T.Tüting Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO. Eur J Immunol 2006; 36:12-20; PMID:16323249; http://dx.doi.org/10.1002/eji.200535602
86. F.Fallarino, P.Puccetti. Toll-like receptor 9-mediated induction of the immunosuppressive pathway of tryptophan catabolism. Eur J Immunol 2006; 36:8-11; PMID:16358364; http://dx.doi.org/10.1002/eji.200535667
87. C.Badoual, S.Hans, N.Merillon, C.Van Ryswick, P.Ravel, N.Benhamouda, E.Levionnois, M.Nizard, A.Si-Mohamed, N.Besnier PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 2013; 73:128-38; PMID:23135914; http://dx.doi.org/10.1158/0008-5472.CAN-12-2606
88. +) T cells. Sci Transl Med 2013; 5:200ra116; PMID:23986400; http://dx.doi.org/10.1126/scitranslmed.3006504
89. O.Kepp, L.Menger, E.Vacchelli, C.Locher, S.Adjemian, T.Yamazaki, I.Martins, A.Q.Sukkurwala, M.Michaud, L.Senovilla Crosstalk between ER stress and immunogenic cell death. Cytokine Growth Factor Rev 2013; 24:311-18; PMID:23787159; http://dx.doi.org/10.1016/j.cytogfr.2013.05.001
90. O.Takikawa, T.Kuroiwa, F.Yamazaki, R.Kido. Mechanism of interferon-gamma action. Characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon-gamma and evaluation of the enzyme-mediated tryptophan degradation in its anticellular activity. J Biol Chem 1988; 263:2041-48; PMID:3123485
91. Y.Ozaki, M.P.Edelstein, D.S.Duch. Induction of indoleamine 2,3-dioxygenase: a mechanism of the antitumor activity of interferon gamma. Proc Natl Acad Sci USA 1988; 85:1242-46; PMID:3124115; http://dx.doi.org/10.1073/pnas.85.4.1242
92. R.Yoshida, S.W.Park, H.Yasui, O.Takikawa. Tryptophan degradation in transplanted tumor cells undergoing rejection. J Immunol 1988; 141:2819-23; PMID:3262668
93. J.D.Shields, I.C.Kourtis, A.A.Tomei, J.M.Roberts, M.A.Swartz. Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science 2010; 328:749-52; PMID:20339029; http://dx.doi.org/10.1126/science.1185837
94. F.Fallarino, U.Grohmann, K.W.Hwang, C.Orabona, C.Vacca, R.Bianchi, M.L.Belladonna, M.C.Fioretti, M.L.Alegre, P.Puccetti. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 2003; 4:1206-12; PMID:14578884; http://dx.doi.org/10.1038/ni1003
95. A.S.Dejean, D.R.Beisner, I.L.Ch'en, Y.M.Kerdiles, A.Babour, K.C.Arden, D.H.Castrillon, R.A.DePinho, S.M.Hedrick. Transcription factor Foxo3 controls the magnitude of T cell immune responses by modulating the function of dendritic cells. Nat Immunol 2009; 10:504-13; PMID:19363483; http://dx.doi.org/10.1038/ni.1729
96. K.A.Schalper. PD-L1 expression and tumor-infiltrating lymphocytes: revisiting the antitumor immune response potential in breast cancer. Oncoimmunology 2014; 3:e29288; PMID:25083339; http://dx.doi.org/10.4161/onci.29288
97. T.Nagato, E.Celis. A novel combinatorial cancer immunotherapy: poly-IC and blockade of the PD-1/PD-L1 pathway. Oncoimmunology 2014; 3:e28440; PMID:25050210; http://dx.doi.org/10.4161/onci.28440
98. D.A.Wainwright, A.L.Chang, M.Dey, I.V.Balyasnikova, C.Kim, A.L.Tobias, Y.Cheng, J.Kim, L.Zhang, J.Qiao Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4 and PD-L1 in mice with brain tumors. Clin Cancer Res 2014; 20:5290-301; PMID:24691018; http://dx.doi.org/10.1158/1078-0432.CCR-14-0514
99. O.Hamid, H.Schmidt, A.Nissan, L.Ridolfi, S.Aamdal, J.Hansson, M.Guida, D.M.Hyams, H.Gómez, L.Bastholt A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med 2011; 9:204; PMID:22123319; http://dx.doi.org/10.1186/1479-5876-9-204
100. E.Vacchelli, I.Vitale, E.Tartour, A.Eggermont, C.Sautes-Fridman, J.Galon, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: anticancer radioimmunotherapy. Oncoimmunology 2013; 2:e25595; PMID:24319634; http://dx.doi.org/10.4161/onci.25595
101. L.Menger, E.Vacchelli, O.Kepp, A.Eggermont, E.Tartour, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: cardiac glycosides and cancer therapy. Oncoimmunology 2013; 2:e23082; PMID:23525565; http://dx.doi.org/10.4161/onci.23082
102. L.Galluzzi, E.Vacchelli, W.H.Fridman, J.Galon, C.Sautes-Fridman, E.Tartour, J.Zucman-Rossi, L.Zitvogel, G.Kroemer. Trial watch: monoclonal antibodies in cancer therapy. Oncoimmunology 2012; 1:28-37; PMID:22720209; http://dx.doi.org/10.4161/onci.1.1.17938
103. M.Friberg, R.Jennings, M.Alsarraj, S.Dessureault, A.Cantor, M.Extermann, A.L.Mellor, D.H.Munn, S.J.Antonia. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int J Cancer 2002; 101:151-55; PMID:12209992; http://dx.doi.org/10.1002/ijc.10645
104. R.M.Hoffman. Tumor growth control with IDO-silencing Salmonella-letter. Cancer Res 2013; 73:4591; PMID:23832662; http://dx.doi.org/10.1158/0008-5472.CAN-12-4719
105. E.R.Manuel, D.J.Diamond. A road less traveled paved by IDO silencing: harnessing the antitumor activity of neutrophils. Oncoimmunology 2013; 2:e23322; PMID:23802075; http://dx.doi.org/10.4161/onci.23322
106. X.Zheng, J.Koropatnick, D.Chen, T.Velenosi, H.Ling, X.Zhang, N.Jiang, B.Navarro, T.E.Ichim, B.Urquhart Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model. Int J Cancer 2013; 132:967-77; PMID:22870862; http://dx.doi.org/10.1002/ijc.27710
107. C.A.Blache, E.R.Manuel, T.I.Kaltcheva, A.N.Wong, J.D.Ellenhorn, B.R.Blazar, D.J.Diamond. Systemic delivery of Salmonella typhimurium transformed with IDO shRNA enhances intratumoral vector colonization and suppresses tumor growth. Cancer Res 2012; 72:6447-56; PMID:23090116; http://dx.doi.org/10.1158/0008-5472.CAN-12-0193
108. D.Wang, Y.Saga, H.Mizukami, N.Sato, H.Nonaka, H.Fujiwara, Y.Takei, S.Machida, O.Takikawa, K.Ozawa Indoleamine-2,3-dioxygenase, an immunosuppressive enzyme that inhibits natural killer cell function, as a useful target for ovarian cancer therapy. Int J Oncol 2012; 40:929-34; PMID:22179492
109. D.Y.Hou, A.J.Muller, M.D.Sharma, J.DuHadaway, T.Banerjee, M.Johnson, A.L.Mellor, G.C.Prendergast, D.H.Munn. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res 2007; 67:792-801; PMID:17234791; http://dx.doi.org/10.1158/0008-5472.CAN-06-2925
110. M.R.Mautino, F.A.Jaipuri, J.Waldo, S.Kumar, J.Adams, C.M.-F.A.M.D.V.N.N.L.C.J.Van AllenC, Marcinowicz-Flick A, Munn D, Vahanian NN, Link CJ. NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy. Cancer Res 2013; 73:491; http://dx.doi.org/10.1158/1538-7445.AM2013-491
111. X.Liu, N.Shin, H.K.Koblish, G.Yang, Q.Wang, K.Wang, L.Leffet, M.J.Hansbury, B.Thomas, M.Rupar Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood 2010; 115:3520-30; PMID:20197554; http://dx.doi.org/10.1182/blood-2009-09-246124
112. H.K.Koblish, M.J.Hansbury, K.J.Bowman, G.Yang, C.L.Neilan, P.J.Haley, T.C.Burn, P.Waeltz, R.B.Sparks, E.W.Yue Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors. Mol Cancer Ther 2010; 9:489-98; PMID:20124451; http://dx.doi.org/10.1158/1535-7163.MCT-09-0628
113. M.Li, A.R.Bolduc, M.N.Hoda, D.N.Gamble, S.B.Dolisca, A.K.Bolduc, K.Hoang, C.Ashley, D.McCall, A.M.Rojiani The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma. J Immunother Cancer 2014; 2:21; PMID:25054064; http://dx.doi.org/10.1186/2051-1426-2-21
114. H.H.Soliman, S.J.Antonia, D.Sullivan, N.Vanahanian, C.J.Link. Overcoming tumor antigen anergy in human malignancies using the novel indoleamine 2,3-dioxygenase (IDO) enzyme inhibitor, 1-methyl-D-tryptophan (1MT). J Clin Oncol 2009; 27:abstr 3004
115. E.Jackson, E.C.Dees, J.S.Kauh, R.D.Harvey, A.Neuger, R.A.S.J.M.S.E.I.-K.R.H.H.S.LushR, Antonia SJ, Minton SE, Ismail-Khan R, Han HS A phase I study of indoximod in combination with docetaxel in metastatic solid tumors. J Clin Oncol 2013; 31:abstr 3026.
116. H.H.Soliman, S.E.Minton, R.Ismail-Khan, H.S.Han, W.Janssen, N.N.Vahanian A phase 2 study of Ad.p53 DC vaccine in combination with indoximod in metastatic solid tumors. J Clin Oncol 2013; 31:abstr 3069.
117. H.H.Soliman, S.E.Minton, R.Ismail-Khan, H.S.Han, N.N.Vahanian, W.J.K.E.L.C.J.S.D.A.S.J.RamseyWJ, Kennedy E, Link CJ, Sullivan D, Antonia SJ. A phase 2 study of docetaxel in combination with indoximod in metastatic breast cancer. J Clin Oncol 2014; 32:abstr TPS3124.
118. Y.Zakharia, T.S.Johnson, H.Colman, N.N.Vahanian, C.J.Link, E.S.R.F.K.F.M.V.J.M.D.KennedyE, Sadek RF, Kong FM, Vender J, Munn D A phase I/II study of the combination of indoximod and temozolomide for adult patients with temozolomide-refractory primary malignant brain tumors. J Clin Oncol 2014; 32:abstr TPS2107.
119. G.L.Beatty, P.J.O'Dwyer, J.Clark, J.G.Shi, R.C.Newton, R.M.J.L.L.G.T.SchaubR, Maleski J, Leopold L, Gajewski T. Phase I study of the safety, pharmacokinetics (PK)and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies. J Clin Oncol 2013; 31:abstr 3025.
120. G.T.Gibney, O.Hamid, T.C.Gangadhar, J.Lutzky, A.J.Olszanski, T.C.B.B.P.D.Z.Y.N.R.C.GajewskiT, Chmielowski B, Boasberg PD, Zhao Y, Newton RC Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma. J Clin Oncol 2014; 32:abstr 3010.
121. T.Banerjee, J.B.Duhadaway, P.Gaspari, E.Sutanto-Ward, D.H.Munn, A.L.Mellor, W.P.Malachowski, G.C.Prendergast, A.J.Muller. A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase. Oncogene 2008; 27:2851-57; PMID:18026137; http://dx.doi.org/10.1038/sj.onc.1210939
122. P.Gaspari, T.Banerjee, W.P.Malachowski, A.J.Muller, G.C.Prendergast, J.DuHadaway, S.Bennett, A.M.Donovan. Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors. J Med Chem 2006; 49:684-92; PMID:16420054; http://dx.doi.org/10.1021/jm0508888
123. G.Carr, M.K.Chung, A.G.Mauk, R.J.Andersen. Synthesis of indoleamine 2,3-dioxygenase inhibitory analogues of the sponge alkaloid exiguamine A. J Med Chem 2008; 51:2634-37; PMID:18393489; http://dx.doi.org/10.1021/jm800143h
124. H.C.Brastianos, E.Vottero, B.O.Patrick, R.Van Soest, T.Matainaho, A.G.Mauk, R.J.Andersen. Exiguamine A, an indoleamine-2,3-dioxygenase (IDO) inhibitor isolated from the marine sponge Neopetrosia exigua. J Am Chem Soc 2006; 128:16046-47; PMID:17165752; http://dx.doi.org/10.1021/ja067211+
125. S.Kumar, D.Jaller, B.Patel, J.M.LaLonde, J.B.DuHadaway, W.P.Malachowski, G.C.Prendergast, A.J.Muller. Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase. J Med Chem 2008; 51:4968-77; PMID:18665584; http://dx.doi.org/10.1021/jm800512z
126. A.Pereira, E.Vottero, M.Roberge, A.G.Mauk, R.J.Andersen. Indoleamine 2,3-dioxygenase inhibitors from the Northeastern Pacific Marine Hydroid Garveia annulata. J Nat Prod 2006; 69:1496-99; PMID:17067170; http://dx.doi.org/10.1021/np060111x
127. F.Francini, A.Pascucci, E.Francini, G.Bargagli, R.Conca, A.Licchetta, G.Roviello, I.Martellucci, G.Chiriacò, S.T.Miano Bevacizumab and weekly docetaxel in patients with metastatic castrate-resistant prostate cancer previously exposed to docetaxel. Prostate Cancer 2011; 2011:258689; PMID:22096653; http://dx.doi.org/10.1155/2011/258689
128. R.Petrioli, A.Pascucci, R.Conca, G.Chiriaco, E.Francini, G.Bargagli, A.I.Fiaschi, A.Manganelli, G.De Rubertis, G.Barbanti Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study. Br J Cancer 2011; 104:613-19; PMID:21285986; http://dx.doi.org/10.1038/bjc.2011.5
129. F.Aranda, E.Vacchelli, A.Eggermont, J.Galon, C.Sautes-Fridman, E.Tartour, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: peptide vaccines in cancer therapy. Oncoimmunology 2013; 2:e26621; PMID:24498550; http://dx.doi.org/10.4161/onci.26621
130. E.Vacchelli, I.Martins, A.Eggermont, W.H.Fridman, J.Galon, C.Sautes-Fridman, E.Tartour, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: peptide vaccines in cancer therapy. Oncoimmunology 2012; 1:1557-76; PMID:23264902; http://dx.doi.org/10.4161/onci.22428
131. E.Vacchelli, A.Eggermont, C.Sautes-Fridman, J.Galon, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: toll-like receptor agonists for cancer therapy. Oncoimmunology 2013; 2:e25238; PMID:24083080; http://dx.doi.org/10.4161/onci.25238
132. F.Aranda, E.Vacchelli, F.Obrist, A.Eggermont, J.Galon, C.Sautes-Fridman, I.Cremer, J.Henrik Ter Meulen, L.Zitvogel, G.Kroemer Trial watch: toll-like receptor agonists in oncological indications. Oncoimmunology 2014; 3:e29179; PMID:25083332; http://dx.doi.org/10.4161/onci.29179
133. J.Pol, N.Bloy, F.Obrist, A.Eggermont, J.Galon, W.Herve Fridman, I.Cremer, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: DNA vaccines for cancer therapy. Oncoimmunology 2014; 3:e28185; PMID:24800178; http://dx.doi.org/10.4161/onci.28185
134. L.Senovilla, E.Vacchelli, P.Garcia, A.Eggermont, W.H.Fridman, J.Galon, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: DNA vaccines for cancer therapy. Oncoimmunology 2013; 2:e23803; PMID:23734328; http://dx.doi.org/10.4161/onci.23803
135. L.Galluzzi, L.Senovilla, E.Vacchelli, A.Eggermont, W.H.Fridman, J.Galon, C.Sautès-Fridman, E.Tartour, L.Zitvogel, G.Kroemer. Trial watch: dendritic cell-based interventions for cancer therapy. Oncoimmunology 2012; 1:1111-34; PMID:23170259; http://dx.doi.org/10.4161/onci.21494
136. E.Vacchelli, I.Vitale, A.Eggermont, W.H.Fridman, J.Fucikova, I.Cremer, J.Galon, E.Tartour, L.Zitvogel, G.Kroemer Trial watch: dendritic cell-based interventions for cancer therapy. Oncoimmunology 2013; 2:e25771; PMID:24286020; http://dx.doi.org/10.4161/onci.25771
137. + T cell-driven lymphopenia without a compensatory IL-7/IL-15 response among high-grade glioma patients treated with radiation and temozolomide. Oncoimmunology 2014; 3:e27357; PMID:24790790; http://dx.doi.org/10.4161/onci.27357
138. T.Z.Iversen, M.K.Brimnes, K.Nikolajsen, R.S.Andersen, S.R.Hadrup, M.H.Andersen, L.Bastholt, I.M.Svane. Depletion of T lymphocytes is correlated with response to temozolomide in melanoma patients. Oncoimmunology 2013; 2:e23288; PMID:23525955; http://dx.doi.org/10.4161/onci.23288
139. G.Kroemer, L.Zitvogel, L.Galluzzi. Victories and deceptions in tumor immunology: Stimuvax®. Oncoimmunology 2013; 2:e23687; PMID:23483762; http://dx.doi.org/10.4161/onci.23687
140. L.Zitvogel, G.Kroemer. Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology 2012; 1:1223-25; PMID:23243584; http://dx.doi.org/10.4161/onci.21335
141. S.A.Gujar, D.Clements, P.W.Lee. Two is better than one: complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses. Oncoimmunology 2014; 3:e27622; PMID:24804161; http://dx.doi.org/10.4161/onci.27622
142. T.J.Waldron, J.G.Quatromoni, T.A.Karakasheva, S.Singhal, A.K.Rustgi. Myeloid derived suppressor cells: targets for therapy. Oncoimmunology 2013; 2:e24117; PMID:23734336; http://dx.doi.org/10.4161/onci.24117
143. L.Galluzzi, L.Senovilla, L.Zitvogel, G.Kroemer. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11:215-33; PMID:22301798; http://dx.doi.org/10.1038/nrd3626
144. L.Zitvogel, L.Galluzzi, M.J.Smyth, G.Kroemer. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013; 39:74-88; PMID:23890065; http://dx.doi.org/10.1016/j.immuni.2013.06.014
145. R.H.Vonderheide, J.M.Burg, R.Mick, J.A.Trosko, D.Li, M.N.Shaik, A.W.Tolcher, O.Hamid. Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. Oncoimmunology 2013; 2:e23033; PMID:23483678; http://dx.doi.org/10.4161/onci.23033
146. J.Hoffmann, I.Vitale, B.Buchmann, L.Galluzzi, W.Schwede, L.Senovilla, W.Skuballa, S.Vivet, R.B.Lichtner, J.M.Vicencio Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone. Cancer Res 2008; 68:5301-08; PMID:18593931; http://dx.doi.org/10.1158/0008-5472.CAN-08-0237
147. C.L.Slingluff, Jr., G.R.Petroni, K.A.Chianese-Bullock, M.E.Smolkin, M.I.Ross, N.B.Haas, M.von Mehren, W.W.Grosh. Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine. J Clin Oncol 2011; 29:2924-32; PMID:21690475; http://dx.doi.org/10.1200/JCO.2010.33.8053
148. + T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res 2009; 15:7036-44; PMID:19903780; http://dx.doi.org/10.1158/1078-0432.CCR-09-1544
149. E.Vacchelli, A.Eggermont, W.H.Fridman, J.Galon, E.Tartour, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: adoptive cell transfer for anticancer immunotherapy. Oncoimmunology 2013; 2:e24238; PMID:23762803; http://dx.doi.org/10.4161/onci.24238
150. L.Galluzzi, E.Vacchelli, A.Eggermont, W.H.Fridman, J.Galon, C.Sautes-Fridman, E.Tartour, L.Zitvogel, G.Kroemer. Trial watch: adoptive cell transfer immunotherapy. Oncoimmunology 2012; 1:306-15; PMID:22737606; http://dx.doi.org/10.4161/onci.19549
151. E.Vacchelli, F.Aranda, F.Obrist, A.Eggermont, J.Galon, I.Cremer, E.Chuang, R.E.Sanborn, J.Lutzky, J.Powderly Trial watch: immunostimulatory cytokines in cancer therapy. Oncoimmunology 2014; 3:e29030; PMID:25083328; http://dx.doi.org/10.4161/onci.29030
152. M.V.Dhodapkar, M.Sznol, B.Zhao, D.Wang, R.D.Carvajal, M.L.Keohan Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci Transl Med 2014; 6:232ra51; PMID:24739759; http://dx.doi.org/10.1126/scitranslmed.3008068
153. E.M.Riedmann. CDX-1401 combined with TLR agonist: positive phase 1 results. Hum Vaccin Immunother 2012; 8:1742; PMID:23980263; http://dx.doi.org/10.4161/hv.19658
154. L.Galluzzi, E.Vacchelli, A.Eggermont, W.H.Fridman, J.Galon, C.Sautes-Fridman, E.Tartour, L.Zitvogel, G.Kroemer. Trial watch: experimental toll-like receptor agonists for cancer therapy. Oncoimmunology 2012; 1:699-716; PMID:22934262; http://dx.doi.org/10.4161/onci.20696
155. E.Vacchelli, L.Galluzzi, A.Eggermont, W.H.Fridman, J.Galon, C.Sautes-Fridman, E.Tartour, L.Zitvogel, G.Kroemer. Trial watch: FDA-approved toll-like receptor agonists for cancer therapy. Oncoimmunology 2012; 1:894-907; PMID:23162757; http://dx.doi.org/10.4161/onci.20931
156. L.Robert, C.Harview, R.Emerson, Wang, S.Mok, B.Homet, B.Comin-Anduix, R.C.Koya, H.Robins, P.C.Tumeh Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes. Oncoimmunology 2014; 3:e29244; PMID:25083336; http://dx.doi.org/10.4161/onci.29244
157. C.Robert, A.Ribas, J.D.Wolchok, F.S.Hodi, O.Hamid, R.Kefford, J.S.Weber, A.M.Joshua, W.J.Hwu, T.C.Gangadhar Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014; 384:1109-17 PMID:25034862; http://dx.doi.org/10.1016/S0140-6736(14)60958-2
158. O.Hamid, C.Robert, A.Daud, F.S.Hodi, W.J.Hwu, R.Kefford, J.D.Wolchok, P.Hersey, R.W.Joseph, J.S.Weber Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369:134-44; PMID:23724846; http://dx.doi.org/10.1056/NEJMoa1305133
159. Z.A.Cooper, D.T.Frederick, V.R.Juneja, R.J.Sullivan, D.P.Lawrence, A.Piris, A.H.Sharpe, D.E.Fisher, K.T.Flaherty, J.A.Wargo. BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes. coimmunology 2013; 2:e26615; PMID:24251082; http://dx.doi.org/10.4161/onci.26615
160. G.Improta, G.Pelosi, E.Tamborini, M.Donia, M.Santinami, F.de Braud, F.Fraggetta. Biological insights into BRAF mutations in melanoma patient: Not mere therapeutic targets. Oncoimmunology 2013; 2:e25594; PMID:24179707; http://dx.doi.org/10.4161/onci.25594
161. J.A.Sosman, K.B.Kim, L.Schuchter, R.Gonzalez, A.C.Pavlick, J.S.Weber, G.A.McArthur, T.E.Hutson, S.J.Moschos, K.T.Flaherty Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366:707-14; PMID:22356324; http://dx.doi.org/10.1056/NEJMoa1112302
162. K.T.Flaherty, I.Puzanov, K.B.Kim, A.Ribas, G.A.McArthur, J.A.Sosman, P.J.O'Dwyer, R.J.Lee, J.F.Grippo, K.Nolop Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363:809-19; PMID:20818844; http://dx.doi.org/10.1056/NEJMoa1002011
163. S.Lob, A.Konigsrainer, R.Schafer, H.G.Rammensee, G.Opelz, P.Terness. Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. Blood 2008; 111:2152-54; PMID:18045970; http://dx.doi.org/10.1182/blood-2007-10-116111
164. F.Qian, J.Liao, J.Villella, R.Edwards, P.Kalinski, S.Lele, P.Shrikant, K.Odunsi. Effects of 1-methyltryptophan stereoisomers on IDO2 enzyme activity and IDO2-mediated arrest of human T cell proliferation. Cancer Immunol Immunother 2012; 61:2013-20; PMID:22527253; http://dx.doi.org/10.1007/s00262-012-1265-x
165. H.J.Yuasa, H.J.Ball, C.J.Austin, N.H.Hunt. 1-L-methyltryptophan is a more effective inhibitor of vertebrate IDO2 enzymes than 1-D-methyltryptophan. Comp Biochem Physiol B Biochem Mol Biol 2010; 157:10-15; PMID:20399882; http://dx.doi.org/10.1016/j.cbpb.2010.04.006
166. S.G.Cady, M.Sono. 1-Methyl-DL-tryptophan, beta-(3-benzofuranyl)-DL-alanine (the oxygen analog of tryptophan), and beta-; 3-benzo(b)thienyl-DL-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase. Arch Biochem Biophys 1991; 291:326-33; PMID:1952947; http://dx.doi.org/10.1016/0003-9861(91)90142-6
167. G.H.Windbichler, H.Hausmaninger, W.Stummvoll, A.H.Graf, C.Kainz, J.Lahodny, U.Denison, E.Müller-Holzner, C.Marth. Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br J Cancer 2000; 82:1138-44; PMID:10735496; http://dx.doi.org/10.1054/bjoc.1999.1053
168. A.Giannopoulos, C.Constantinides, E.Fokaeas, C.Stravodimos, M.Giannopoulou, A.Kyroudi, A.Gounaris. The immunomodulating effect of interferon-gamma intravesical instillations in preventing bladder cancer recurrence. Clin Cancer Res 2003; 9:5550-58; PMID:14654535
169. + T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 2005; 115:739-46; PMID:15696196; http://dx.doi.org/10.1172/JCI23373
170. B.K.Choi, T.Asai, D.S.Vinay, Y.H.Kim, B.S.Kwon. 4-1BB-mediated amelioration of experimental autoimmune uveoretinitis is caused by indoleamine 2,3-dioxygenase-dependent mechanisms. Cytokine 2006; 34:233-42; PMID:16899371; http://dx.doi.org/10.1016/j.cyto.2006.04.008
171. S.K.Seo, J.H.Choi, Y.H.Kim, W.J.Kang, H.Y.Park, J.H.Suh, B.K.Choi, D.S.Vinay, B.S.Kwon. 4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat Med 2004; 10:1088-94; PMID:15448685; http://dx.doi.org/10.1038/nm1107
172. + T cells. Cancer Res 2002; 62:3459-65; PMID:12067989
173. I.Melero, W.W.Shuford, S.A.Newby, A.Aruffo, J.A.Ledbetter, K.E.Hellstrom, R.S.Mittler, L.Chen. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 1997; 3:682-85; PMID:9176498; http://dx.doi.org/10.1038/nm0697-682
174. R.Metz, C.Smith, J.B.DuHadaway, P.Chandler, B.Baban, L.M.Merlo, E.Pigott, M.P.Keough, S.Rust, A.L.Mellor IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation. Int Immunol 2014; 26:357-67; PMID:24402311; http://dx.doi.org/10.1093/intimm/dxt073
175. T.Okamoto, S.Tone, H.Kanouchi, C.Miyawaki, S.Ono, Y.Minatogawa. Transcriptional regulation of indoleamine 2,3-dioxygenase (IDO) by tryptophan and its analogue: down-regulation of the indoleamine 2,3-dioxygenase (IDO) transcription by tryptophan and its analogue. Cytotechnology 2007; 54:107-13; PMID:19003025; http://dx.doi.org/10.1007/s10616-007-9081-4
176. C.A.Opitz, U.M.Litzenburger, U.Opitz, F.Sahm, K.Ochs, C.Lutz, W.Wick, M.Platten. The indoleamine-2,3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDO1 in human cancer cells. PLoS One 2011; 6:e19823; PMID:21625531; http://dx.doi.org/10.1371/journal.pone.0019823
177. Y.Kudo, C.A.Boyd. Characterisation of L-tryptophan transporters in human placenta: a comparison of brush border and basal membrane vesicles. J Physiol 2001; 531:405-16; PMID:11230513; http://dx.doi.org/10.1111/j.1469-7793.2001.0405i.x